What changed
$ABT — Develops and sells healthcare products and diagnostics.
🎯 Q1 FY26 | Rev $11B | EPS $1.15 vs $1.15 🟢 | Margin 26.0%
💡 Consensus expects Abbott to deliver steady mid-single-digit organic growth and margin expansion as medical device volumes normalize. However, the market is underestimating the integration risk and dilution from the Exact Sciences acquisition, which adds debt and integration costs without immediate EPS accretion.
🏢 Business Quality: 8/10 | Valuation: fair
📉 Reward/Risk: Upside 8% to $98.50 (consensus PT) vs. downside 12% to $80 (if integration disappoints). Ratio: 0.67x, unfavorable.
🔮 Catalyst: Q2 2026 earnings (late July): organic revenue growth vs. guidance of ~5%; free cash flow conversion rate. Failure signal: organic growth below 4% or FCF margin below 15%.
💰 Entry: Current price $91.25 is near the upper end of the 12-month range ($78-$93).
Also in play: $ALSN $WAB $GBX $TRN $CAT $CMC